≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
UT-34 UT-34 is a potent, selective and orally bioavailable second-generation androgen receptor (AR) pan antagonist and degrader with IC50 of 203.46 nM, 80.78 nM and 94.17 nM for wild-type, T877A and W741L AR, respectively. UT-34 is a potential next-generation therapeutic for enzalutamide-resistant prostate cancer.
Targets
AR-T877A (Cell-free assay); AR-W741L (Cell-free assay); AR-WT (Cell-free assay) 80.78 nM; 94.17 nM; 203.46 nM
In vitro
UT-34 inhibits the wild-type and LBD-mutant ARs comparably and inhibits the in vitro proliferation. UT-34 promotes a conformation that is distinct from the LBD-binding competitive antagonist enzalutamide and degrades the AR through the ubiquitin proteasome mechanism. UT-34 has a broad safety margin and exhibits no cross-reactivity with Gprotein-coupled receptor kinase and nuclear receptor family members.
In vivo
UT-34 inhibits the wild-type and LBD-mutant ARs comparably and inhibits the in vivo growth of enzalutamide-sensitive and -resistant prostate cancer xenografts. In preclinical models, UT-34 induces the regression of enzalutamide-resistant tumors at doses when the AR is degraded; but, at lower doses, when the AR is just antagonized, it inhibits, without shrinking, the tumors.
Cell Research(from reference)
Cell lines：LNCaP, PC-3, HEK-293, ZR-75-1, MDA-MB-453, VCaP, 22RV1, and COS7 cell lines
Concentrations：0.1 μM, 1 μM, 10 μM
Incubation Time：30 min, 24 h, 48 h
| ALogP | 2.05 |
|---|---|
| Recuento HBD | 1 |
| Enlace rotable | 5 |
| Pubchem Sid | 488202768 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488202768 |
| Sonrisas canónicas | CC(CN1C=C(C=N1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O |
| IUPAC Name | (2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluoropyrazol-1-yl)-2-hydroxy-2-methylpropanamide |
| InChIKey | YDRMSDHDYRAUBR-AWEZNQCLSA-N |
| INCHI | 1S/C15H12F4N4O2/c1-14(25,8-23-7-10(16)6-21-23)13(24)22-11-3-2-9(5-20)12(4-11)15(17,18)19/h2-4,6-7,25H,8H2,1H3,(H,22,24)/t14-/m0/s1 |
| Isómeros SMILES | C[C@](CN1C=C(C=N1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O |
| PubChem CID | 132214622 |
| Peso molecular | 356.27 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
 D2328233 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| D2328234 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| D2328235 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| D2328236 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| D2328262 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| E2304036 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| E2304110 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| E2304115 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| E2304119 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| E2304125 | Certificate of Analysis | Feb 05, 2026 | U414245 |
| Solubilidad | Solubility (25°C) In vitro DMSO: 71 mg/mL (199.28 mM); Ethanol: 71 mg/mL (199.28 mM); Water: Insoluble; |
|---|---|
| DMSO (mg/ml) Solubilidad máxima | 71 |
| DMSO (mM) Solubilidad máxima | 199.287057568698 |
| Agua (mg/ml) Solubilidad máxima | ＜1 |
| Peso molecular | 356.270 g/mol |
| XLogP3 | 1.300 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 356.09 Da |
| Monoisotopic Mass | 356.09 Da |
| Topological Polar Surface Area | 90.900 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 549.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
